Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22301802 | 0.88 | HRH3 (0.35) | SIGMAR1CYP1A2CYP2D6ALOX15GNAO1 | |
| SCHEMBL25571583 | 0.87 | NCF1 (0.41) | NCF1ACHESIGMAR1GNAO1GNAI3 | |
| SCHEMBL22565121 | 0.84 | NCF1 (0.41) | NCF1ACHESIGMAR1 | |
| SCHEMBL25571577 | 0.79 | CYP1A2 (0.36) | NCF1ACHESIGMAR1CYP1A2CYP2D6 | |
| SCHEMBL26530923 | 0.79 | NCF1 (0.39) | NCF1ACHESIGMAR1GNAO1GNAI3 | |
| SCHEMBL27290168 | 0.79 | NCF1 (0.39) | NCF1ACHESIGMAR1 | |
| SCHEMBL14081460 | 0.78 | NCF1 (0.50) | NCF1ACHESIGMAR1CYP1A2GNAO1 | |
| SCHEMBL24267159 | 0.77 | NCF1 (0.38) | NCF1ACHESIGMAR1CYP1A2CYP2D6 | |
| SCHEMBL24475619 | 0.77 | VCP (0.39) | NCF1ACHESIGMAR1CYP1A2CYP2D6 | |
| SCHEMBL25090036 | 0.77 | TSHR (0.37) | SIGMAR1CYP1A2CYP2D6ALOX15GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | NCF1 3023/4885ACHE 3611/4885SIGMAR1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.